Poor
Partially Aligned
Patient Risk:
Moderate
Summary
The AI output contains some label-consistent statements about thyroid C-cell tumors and contraindications, but it also includes a non-auditable assessment referencing missing/unclear label content and does not provide a clear, assessable mapping to the FDA label for the specific claims being evaluated.
Category Scores
Accurate Statements
The label states tirzepatide caused a dose- and treatment-duration-dependent increase in thyroid C-cell tumors in rats, and it is unknown whether this causes thyroid C-cell tumors (including MTC) in humans.
Label excerpts: Section 5.1 (and also mirrored in Section 13.1/17 excerpts provided).
The label contraindicates ZEPBOUND in patients with a personal or family history of MTC or in patients with MEN 2.
Label excerpt: Section 4 (with reference to 5.1).
The label counsels patients to report symptoms of thyroid tumors (e.g., lump in the neck, persistent hoarseness, dysphagia, dyspnea) and references risk to be communicated.
Label excerpts: Section 5.1 and Section 17.
Unsupported Statements
“No specific user claim text was provided beyond the general topic; assessment is based only on the provided label excerpts…”
While a lack of specific claim text may be true, the response then proceeds to rate/support claims and also includes other blocks that indicate inability to verify; the overall assessment is not auditable as presented.
“Supported: yes / Contradicted: no / Evidence Summary: The label explicitly states…”
This conclusion is not verifiable against an actual user claim because the provided text indicates no exact user claim text was supplied; thus the support verdict cannot be reliably confirmed as claim-level alignment.
The subsequent block claims the assessment is “not_auditable_as_provided” due to missing product name/full label text, and that sections cannot be verified—yet earlier parts assert support.
The combined output is internally inconsistent on audibility and therefore does not cleanly establish claim-to-label alignment.
Contradictions
Important Omissions
A clear, single, claim-by-claim comparison between an exact user assertion and the corresponding FDA label text (with explicit quoted/section-cited alignment for that exact claim).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Because the evaluation is not fully auditable at the claim level (and includes conflicting statements about audibility), there is a moderate risk that incorrect or non-evaluable claims could be treated as supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
The output is not cleanly auditable: it mixes a support conclusion with another block stating the assessment is not auditable, and it lacks a specific claim-to-label comparison for the exact asserted text.
Suggested Improvement
Provide the exact user claim(s) to be evaluated and then map each claim to the corresponding FDA label excerpt(s) by directly quoting the relevant sentences; ensure the final verdict (supported/unsupported/contradicted) is consistent and does not state both auditable support and non-auditable inability.